Sarepta Therapeutics Inc
SRPT
View Detailed Chart
24.450USD
+0.440+1.83%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
2.39BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.83%
5 Days
+4.04%
1 Month
+7.99%
6 Months
-61.50%
Year to Date
-79.89%
1 Year
-80.17%
View Detailed Chart
TradingKey Stock Score of Sarepta Therapeutics Inc
Currency: USD Updated: 2025-11-03Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sarepta Therapeutics Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
29
analysts
Hold
Current Rating
32.399
Target Price
+34.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sarepta Therapeutics Inc Highlights
StrengthsRisks
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 103.85% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -45.04, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 84.37M shares, decreasing 19.56% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 63.00K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 2.36.
News
Sarepta Surges Over 14% as FDA Lifts Shipping Ban; Wall Street Anticipates Doubling in Stock Price
TradingKey - Sarepta Therapeutics (SRPT.US) announced on Monday, July 28, that it has resumed shipments of its gene therapy Elevidys in the U.S., following an authorization from the U.S. Food and Drug Administration (FDA). The company's stock spiked over 20% on Tuesday, closing up 14.21% at $15.83,
TradingKeyWed, Jul 30
Sarepta down after pausing Elevidys shipments in US
Shares of Sarepta Therapeutics SRPT.O down 1.7% at $13.10; they fell nearly 8% in premarket trading
ReutersTue, Jul 22
Financial Indicators
EPS
No Data
Total revenue
No Data
Sarepta Therapeutics Inc Info
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Ticker SymbolSRPT
CompanySarepta Therapeutics Inc
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Websitehttps://www.sarepta.com/
Related Instruments
+3.90%
-1.38%
-2.79%
-0.83%
+0.06%
-4.06%
-0.71%
-0.71%
+1.89%
+0.04%
-1.05%
+0.10%
+1.10%
-0.11%
-1.09%
+1.19%
-1.47%
+0.18%
-4.82%
-0.29%Popular Symbols
